With URL, Takeda Looks To Become U.S. Gout Therapy Provider Of Choice
This article was originally published in The Pink Sheet Daily
In purchasing privately held URL for $800 million, Takeda acquires gout drug Colcrys, which it will market alongside Uloric.
You may also be interested in...
Takeda’s Strategic Run Up To Nycomed
With the acquisition of Nycomed, Takeda’s long-standing strategy for becoming a world-class pharma has come into focus. The company spent much of the past decade building up its pipeline, globalizing R&D and importing Western staff, assets, platforms and processes. It also began a hectic period of M&A unparalleled among Japanese companies, culminating in 2011 with its acquisition of Nycomed. Now its focus will need to shift from big acquisitions and organizational makeover to execution.
Deals Of The Week: Shire/Pervasis, Takeda/URL, Amgen/KAI
By adding Pervasis’ endothelial cell technology to the expertise it added with last year’s buyout of Advanced BioHealing, Shire is hoping to build its Regenerative Medicine unit into another powerhouse division, like its Human Genetic Therapies unit.
Regeneron’s Arcalyst Gets Advisory Committee For Niche Gout Indication
FDA’s Arthritis Advisory Committee will consider the interleukin-1 blocker for prevention of gout flares during initiation of uric-acid lowering therapy. Analysts say Arcalyst could have an easier time than Novartis’ Ilaris, which the panel felt had serious infection safety issues.